Floatz logo

Saruparib

Metastatic Prostate Carcinoma

AstraZenecaSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

228 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
AXUMIN
VA Greater Los Angeles Healthcare System
Phase 4BBB
Leuporelin
Mayo Clinic
Phase 4BBB
Abiraterone
Mayo Clinic
Phase 4BB
Prednisone
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB

View all 50 →

Same molecule, other indications

Saruparib is also rated in:

small cell lung carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
prostate cancerActive
B
Indicative · Phase 3
58 / 100
View asset →
breast cancerActive
CCC
Indicative · Phase 3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →